Arcoma ABOSTO:ARCOMA +6.95%75 Gross Margin % is 39.97% as of Mar. 2026, which is 1% above its 10-year median of 39.54. GuruFocus rates OSTO:ARCOMA with a GF Score™ of 75/100 and a GF Value™ of kr7.85 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Arcoma AB ranks worse than 68.45% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Arcoma AB's Gross Profit for the
three
months ended in Mar. 2026 was kr12.4 Mil. Arcoma AB's Revenue for the
three
months ended in Mar. 2026 was kr31.1 Mil. Therefore, Arcoma AB's Gross Margin % for the quarter that ended in Mar. 2026 was 39.97%.
The historical rank and industry rank for Arcoma AB's Gross Margin % or its related term are showing as below:
OSTO:ARCOMA'
s Gross Margin % Range Over the Past 10 Years
Min: 35.53 Med: 39.54 Max: 42.63
Current: 39.85
During the past 13 years, the highestGross Margin % of Arcoma AB was 42.63%. The lowest was 35.53%. And the median was 39.54%.
OSTO:ARCOMA's Gross Margin % is ranked worse than 68.45% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 51.94
vs OSTO:ARCOMA: 39.85
Arcoma AB had a gross margin of 39.97% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Arcoma AB was 1.40% per year.
Arcoma AB (OSTO:ARCOMA) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Arcoma AB had a gross margin of 39.97% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Arcoma AB Gross Margin % Related Terms
Arcoma AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for Arcoma AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ARCOMA vs ABT, SYK, MDT: Gross Margin % Comparison
For the Medical Devices subindustry, Arcoma AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcoma AB Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Arcoma AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Arcoma AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Arcoma AB (OSTO:ARCOMA) has a Gross Margin % of 39.97% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Arcoma AB and its competitors. This is near median its historical median of 39.54. Over the past decade, Arcoma AB's Gross Margin % has ranged from 35.53 to 42.63. According to the industry distribution chart, Arcoma AB ranks #551 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 68.4%.
Is Arcoma AB's Gross Margin % too high?
Arcoma AB's current Gross Margin % of 39.97% is near median its 10-year median of 39.54. Over the past 10 years, this metric has ranged from a low of 35.53 to a high of 42.63. The Medical Devices & Instruments industry median Gross Margin % is 51.94. Arcoma AB's value of 39.97% is 23% below this industry median. Based on the distribution chart, Arcoma AB ranks #551 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Arcoma AB has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcoma AB's Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Arcoma AB ranks #551 out of 805 companies for Gross Margin %. This places Arcoma AB in the lower half of its industry. The industry median Gross Margin % is 51.94. Arcoma AB's value of 39.97% is 23% below this benchmark. Historically, Arcoma AB's own Gross Margin % has ranged from 35.53 to 42.63 over the past decade. While the company's 10-year median is 39.54 vs. the industry median of 51.94, Arcoma AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 51.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcoma AB's current Gross Margin % of 39.97% is 23% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Arcoma AB and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 51.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcoma AB's current Gross Margin % is 39.97%, which is near median its own 10-year median of 39.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcoma AB stock overvalued right now?
Based on GuruFocus' analysis, Arcoma AB (OSTO:ARCOMA) is currently considered Modestly Overvalued. The stock's GF Value™ is kr7.85, compared to a current price of kr8.92 — trading 13.6% above its estimated fair value. The current Gross Margin % is 39.97%, which is near median its 10-year median of 39.54 and 23% below the Medical Devices & Instruments industry median of 51.94. Arcoma AB's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Arcoma AB (OSTO:ARCOMA), the current Gross Margin % is 39.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcoma AB (OSTO:ARCOMA) Overvalued in 2026?
Based on GuruFocus' analysis, Arcoma AB stock appears to be overvalued.
The current stock price of kr8.92 is trading 13.6% above its estimated GF Value™ of kr7.85.
GuruFocus considers Arcoma AB to be Modestly Overvalued.
Key valuation signals for OSTO:ARCOMA:
Gross Margin %: 39.97% (near median its 10-year median of 39.54)
GF Value™: kr7.85 vs. price of kr8.92 (13.6% above fair value)
Industry Position: 23% below the Medical Devices & Instruments median (#551 of 805)
No single metric tells the full story. See the OSTO:ARCOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
75GF Score
Get the complete analysis for OSTO:ARCOMA
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ARCOMA has been successfully added to your 
